Idorsia Pharmaceuticals Ltd and Johnson & Johnson’s aprocitentan has succeeded in a Phase III resistant hypertension trial with plans in place for a US filing by year end, which could see it become the first drug of its class on the market.
Idorsia/J&J’s Aprocitentan Hits Phase III Mark, Could Become First ET-1 Antagonist For Hypertension
The first-in-class ET-1 receptor antagonist has met the primary endpoint in a pivotal resistant hypertension trial, sparking filing plans that could see the drug establish a stronghold in the multi-billion dollar market.
